NCT00093639View on ClinicalTrials.gov

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Leukemia
Interventions
DRUG

everolimus

DRUG

imatinib mesylate

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00093639 - Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | Biotech Hunter | Biotech Hunter